Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases. The ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...

Drug developers can now leverage large language models to draft regulatory documents, which they hope will shorten the time ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

A bill under consideration in the legislature would position Iowa to immediately allow prescriptions of a synthetic version ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...

“Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495 ... in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q filed for the quarter ended ...